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ABSTRACT 
 
Glucocorticoids (GCs) exert wide-spread actions in central nervous system ranging 
from gene transcription, cellular signaling, modulation of synaptic structure and 
transmission, glial responses to altered neuronal circuitry and behavior through the 
activation of two steroid hormone receptors, glucocorticoid receptor (NR3C1, GR) and 
mineralocorticoid receptor (NR3C2, MR). These highly-related receptors exert both 
genomic and non-genomic actions in the brain, which are context-dependent and essential 
for adaptive responses to stress resulting in modulations of behavior, learning and 
memory processes. Thus, GCs through their receptors are implicated in neural plasticity 
as they modulate the dendritic and synaptic structure of neurons as well as the survival 
and fate of newly-generated cells (neuro- and glio-genesis) in adult brain. GCs are also 
important in fetal brain programming as inappropriate variations in their levels during 
critical developmental periods are suggested to be casually related to the development of 
brain pathologies and maladaptive responses of hypothalamic-pituitary adrenal (HPA) 
axis to stress during adulthood. They regulate immune responses in brain, which have 
important consequences for neuronal survival. In situations of chronic stress and HPA 
axis dysfunction resulting in chronically high or low GCs levels, a multitude of 
molecular, structural and functional changes occur in the brain, eventually leading to 
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maladaptive behavior. In fact, clinical studies suggest a causal relation of deregulated GC 
responses with development of neurodegenerative disorders such as Alzheimer´s (AD) 
and Parkinson‘s (PD) diseases. AD and PD patients have high levels of circulating 
cortisol while animal studies suggest that this chronic GC elevation participates in 
neurodegenerative processes in both AD and PD pathologies. This chapter will focus on 
the role of HPA axis and GCs on neurodegenerative processes involved in AD and PD 
pathogenesis. 
 
Keywords: glucocorticoids, neurodegeneration, Alzheimer‘s disease, Parkinson‘s disease, 
epigenetics 
 
 
INTRODUCTION 
 
Glucocorticoid (GC) hormone is synthesized and released into systemic circulation from 
adrenal glands following activation of hypothalamic-pituitary-adrenal (HPA) axis, which 
entails synthesis of corticotropin-releasing hormone (CRH) and arginine vasopressin (AVP) 
by paraventricular neurons (PVN) of hypothalamus and their release from median eminence 
into portal blood. These hormones stimulate the synthesis of adrenocorticotropic hormone 
(ACTH) in the anterior pituitary, which when released into general circulation binds to ACTH 
receptor (melanocortin type II receptor) in adrenal glands promoting GC synthesis from 
cholesterol. GC release by HPA axis is under circadian control and occurs in an oscillatory 
pattern or ultradian rhythm that varies in amplitude according to the time of day (peak in the 
morning and trough in the evening/night in diurnal animals including humans and vice versa 
in nocturnal animals, e.g., rodents). In addition, there is a surge of GC release in response to a 
stress stimulus, which can be either psychogenic (e.g., fear) or physical (e.g., cellular lesion 
or pathogen invasion). In response to stress, GCs exert critical adaptive functions by 
modulating most biological processes (e.g., metabolism, cardiovascular and immune systems 
as well as behavior); and through feedback inhibition of HPA axis they play a role in 
terminating the stress response as well as facilitating the restoration of physiological 
homeostasis [1]. In addition to their role in stress response, appropriate GCs levels are 
important during development, for example in cell maturation, and in the differentiation of 
lungs, kidneys and brain [2-4].  
It is now thoroughly established that GCs have the capacity to profoundly modulate 
different brain functions, as well, increasing evidence points to their role in brain 
development. The appreciation that brain is a key target of this circulating adrenal steroid 
hormone emerged from the pioneering work, principally by the laboratories of McEwen and 
de Kloet, on identification and biochemical characterization of two receptors in the 
hippocampus to which GCs bind - the mineralocorticoid receptor (MR) and glucocorticoid 
receptor (GR) [5, 6]. Since then, GR presence in brain was observed to be widespread with 
every cell type expressing this receptor in contrast to MR expression, which is more 
restricted. MR is expressed by the neurons of the limbic system, i.e., hippocampus, locus 
coeruleus, amygdala, prefrontal cortex and nucleus of the solitary tract, as well as neurons of 
hypothalamus. MR is also present in non-neuronal cells, namely in glia and in epithelial cells 
of choroid plexus and ependyma [7]. In brain, 
3
[H] corticosterone binding assays showed that 
MR has 10-fold higher affinity (Kd= 0.5 nM) for GCs compared to GR (Kd= 5 nM), which 
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means that at basal GC levels, MR is occupied and activated [8] whereas GR is only activated 
when GC levels reach a certain level as it happens in circadian peak and during stress [9]. GC 
actions are pleiotropic, the principle factors determining their functions are: a) circulating 
levels with accessibility to each cell type and b) context in which the receptors are activated. 
GC levels are tightly regulated at each level of HPA axis and this is important in ensuring that 
stress response is correctly executed. Deregulated HPA axis resulting in sustained high or low 
GC levels are implicated in different diseases, for example disorders of metabolism (e.g., 
diabetes, obesity), immune (e.g., rheumatoid arthritis) and nervous systems (e.g., depression) 
[10-12].  
Synthetic GCs (e.g., dexamethasone, methylprednisolone) are routinely used in clinical 
situations, particularly in disorders with an inflammatory component such as rheumatoid 
arthritis or brain edema as they exert powerful anti-inflammatory and immunosuppressive 
actions. However, prolonged GC use suppresses HPA axis resulting in harmful side effects 
such as increased risk of infection, hyperglycemia, weight gain, behavioral or cognitive 
problems. Interestingly, GCs are now also used clinically in neonates, as endogenous GCs are 
required for fetal lung maturation as they promote the production of lung surfactant. This 
could affect the programming or subsequent responsiveness of HPA axis particularly with 
regards to stress responses in adults [13]. Thus prolonged GC exposure or exposure to high 
levels of GC in specific developmental windows such as the prenatal and perinatal period can 
impair the HPA axis negative feedback, increasing the propensity for developing 
neuropsychiatric and metabolic disorders [14].  
Glucocorticoid actions through MR and GR in brain have been particularly studied in 
relation to glutamatergic as well as monoaminergic (e.g., dopaminergic and serotonergic) 
systems, which have wide-range consequences from mood behaviors to cognition. Several 
excellent reviews already exist on our current understanding of neuronal functions of GCsin 
brain via these two receptors [15-19]. Our aim in this chapter is to describe how their actions 
in neurons and glia impact the neurodegenerative processes, emphasizing on Alzheimer (AD) 
and Parkinson diseases (PD). One of the arguments for their implication relates to GC 
functions being exquisitely dependent on environmental changes, and in this regard, both 
genetic susceptibility and environmental factors are believed to play key roles in the etiology 
of these neurodegenerative diseases. Most of our current understanding of GCs involvement 
in brain disorders relates to the functions of GR as this receptor plays a major role in stress 
responses. Thus, before describing our current knowledge of GCs in neurodegeneration, we 
reiterate the regulation of GC release by HPA axis and functional activity of GR as both are 
likely affected in AD and PD as discussed below.  
 
 
REGULATION OF GC RELEASE AND AVAILABILITY 
 
Paraventricular nucleus (PVN) of hypothalamus receives integrated information from 
suprachiasmatic nucleus for circadian control of GCs and from the limbic system for 
psychogenic stress-induced GC release [20, 21]. In stress-induced GC release, limbic 
structures such as amygdala are involved in stimulating PVN neurons to synthesize CRH 
whilst hippocampus plays a crucial role in negative feedback inhibition of the HPA axis [22]. 
The fast feedback inhibition of HPA axis following acute stress is important to prevent 
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depletion of GC needed for both successive stress and ultradian release, which interestingly is 
impaired in aging as well as in patients suffering from depression. Both MR and GR at 
hypothalamic and hippocampal levels play an important role in regulating the activity of PVN 
neurons. In addition GR in anterior pituitary was found to regulate pulsatile ACTH release 
[23]. HPA axis is also activated in response to cellular lesion or pathogen invasion by pro-
inflammatory cytokines such as IL-1, IL-6 or TNF- released by either peripheral immune 
cells or microglia [24]. IL-6 through activation of its receptor can also stimulate ACTH 
release from anterior pituitary and GC from adrenal glands [25].  
The availability of GCs to neurons and non-neuronal cells in brain is controlled in two 
ways. Firstly, in the blood, most GCc are bound to corticosteroid binding globulin (CBG) 
whose levels are down regulated by stress thereby increasing free-circulating GC levels [26]. 
Secondly, once inside the cells, the availability of GC for GR activation is controlled by GC-
metabolizing enzymes: 11--hydroxysteroid dehydrogenase type I (HSD111),   which 
regenerates active glucocorticoids (e.g., cortisol from cortisone) thus amplifying GR 
activation. In addition, 11--hydroxysteroid dehydrogenase type II (HSD112)  has an 
opposite function, i.e., increasing the inactive form of GC. Using mice deficient for 
HSD111, previous studies have shown that these mice are protected from hippocampal 
memory impairments associated with aging. However, cognitive problems arise normally 
because GR activity predominates due to high GC levels catalyzed by this enzyme [27, 28].  
 
 
GENOMIC AND NON-GENOMIC ACTIONS OF GLUCOCORTICOID 
RECEPTOR (GR)  
 
GR exerts both genomic and non-genomic actions in brain. The genomic actions of GR 
pertain to its ligand-activated transcriptional activity. Non-liganded GR in the cytoplasm is 
normally in complex with chaperone proteins such as heat shock proteins 90, 70, 40, 23 as 
well as immunophilins such as FKBP51 and 52. Upon GC binding, the conformational 
change of the complex results in exposure of nuclear localization signal of GR, which allows 
importin-mediated translocation of GR into the nucleus. Recent studies highlight the 
importance of correlation between GR transcriptional activity and ultradian pulsatile nature of 
GCs for generation of appropriate response to stress stimulus [29, 30].  
GR protein is comprised of N-terminal transactivation domain which is important site for 
GR co-regulatory binding proteins such as cAMP-response-element binding protein binding 
protein (CBP), it also contains phosphorylation sites, e.g., serine 203, serine221 and serine 
226. The central zinc-finger DNA-binding domain is important for the GR binding to the so-
called Glucocorticoid Response Elements (GREs), which are present in promoters of GR 
target genes. The carboxy-terminal domain is the site of GC binding to GR as well as co-
activators such as histone acetylases or co-repressors. The transcriptional regulation by GR is 
both cell-type and context-dependent. GR can regulate transcription by: a) direct binding as 
homo-dimers to GRE DNA sequences to stimulate transcription, e.g., mitogen-activated 
protein kinase phosphatase-1 gene; b) direct binding to negative GRE elements to repress 
transcription, e.g., CRH or ACTH receptor genes; c) trans-repression or ―tethering‖ i.e., 
association with other transcriptional factors to inhibit their transcriptional activity. This 
mechanism is by far the most notable in immune cells where GR regulates transcription of 
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nuclear factor kappa-light-chain-enhancer of activated B cells (NF-B), activator protein-1 
(AP-1) and members of interferon regulatory transcription factors (IRFs). In brain, 
identification of GR-modulated genes is difficult due to anatomical complexity and cellular 
heterogeneity. Nevertheless, transcriptomic studies in the hippocampus have identified 
functional classes of genes modulated by GR which include genes coding for neurotransmitter 
catabolism, neurotrophic factors and their receptors, signal transduction, energy metabolism 
and cell adhesion [31].  
The genomic actions of GR are slow in onset and long lasting. In contrast, GR exerts 
non-genomic actions at plasma membrane of neurons, which are rapid (seconds to minutes), 
involve alterations in neuronal excitability and are dependent on the context of the signal. The 
non-genomic actions of GR at the membranes also involve activation of down-stream 
signaling pathways involving kinases such as ERK, AKT, PKC and PKA [32]. Altogether, 
this provides a surprising diversity and complexity of GC modulation of gene expression and 
cellular signaling.  
 
 
EPIGENETIC REGULATION OF GR  
 
Animal studies confirm earlier anecdotal observations in humans indicating that early life 
adverse experience has a profound impact on adult behavior. Early life stress or exposure to 
GC (endogenous or exogenous) may induce neuroendocrine programming, subsequently 
altering offspring's growth, metabolism, immune system and even the stress response as 
previously mentioned. These observations derive from both animal and human studies, where 
an alteration in the activity of the HPA axis was found [14, 33, 34]. Such prenatal programing 
may be an evolutionary mode of shaping internal characteristics of the developing organisms 
in order to adapt to the environment. However, such modifications might ultimately result in 
the development of long-term diseases, from metabolic syndromes to psychiatric disorders 
[35-39]. 
This long-lasting effect of early life experiences in brain function and behavior appears to 
be mediated (at least partially) by epigenetic mechanisms [14, 34, 40]. In the last years, 
considerable progress has been made in untangling the epigenetic alterations induced by 
stress/GC. However, most of the studies are merely correlative and the mechanism through 
which stress/GC induce epigenetic programing remains completely unkown. 
One way of buffering the impact of maternal GC exposure in the developing fetus is by 
converting cortisol/corticosterone into inactive metabolites through the action of placental 
HSD112. However, some studies indicate that maternal adversity can increase the 
methylation at specific CpG sites within the HSD112 gene promoter and lead to a down-
regulation of this enzyme [41, 42], which may allow excessive levels of GC to reach the fetus 
and program different organs and systems. The first evidence of brain epigenetic programing 
induced by early life adversity was reported by Meaney and colleagues, which showed that 
natural variations in maternal behavior were correlated with DNA methylation levels of a 
neuron-specific exon 17 promoter of the GR gene.  
Briefly, male rats reared by ―good dams‖ (i.e., those that presented high pup licking and 
grooming) demonstrated lower levels of stress response, greater performance on cognitive 
tasks and larger exploratory activity in a novel environment, compared to the offspring of 
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―bad dams‖; this was associated with a differential methylation of this specific region of the 
GR promoter [43, 44]. Importantly, these results were later replicated in humans showing 
individuals with childhood stressful experiences (abuse during childhood), presented 
hypermethylation of this region, in comparison to non-abused individuals [45].  
Later studies revealed an increased methylation of a CpG-rich region in the promoter and 
exon1F of the GR gene in the cord blood of newborns of mothers with depressed mood 
during the third trimester of gestation [46]. Importantly, this pattern on methylation of the GR 
gene occurred only in the offspring (and not the mothers), correlated with levels of response 
to stress in infants at 3 months of age, and persisted beyond infancy. Similarly, pregnancy- 
related anxiety is associated with the methylation state of the GR gene in the child [47]. These 
findings suggest a common effect of parental care in both rodents and humans on the 
epigenetic regulation of hippocampal GR expression. One question that still remains is 
whether these epigenetic changes are the cause of maladaptive behaviors or a mere 
adaptation, in the light of evidence showing that healthy individuals with a history of 
childhood adversity can also present increased GR methylation and an attenuated cortisol 
response to the dexamethasone test [48]. In this perspective, such adversity-induced 
epigenetic changes may predispose the individual to disease (in combination with other 
genetic or extrinsic factors) but are not the cause per se. 
In addition, other pivotal stress players are also affected by early life stress/GC exposure. 
For example, mice, in a model of early-life stress present hypersecretion of corticosterone, 
alterations in passive stress coping and memory followed by a persistent increase in arginine 
vasopressin expression in neurons of the hypothalamic PVN due to sustained DNA 
hypomethylation of CpG residues that serve as DNA-binding sites for the methyl CpG-
binding protein 2 (MeCP2) [49]. In addition, stress/GC exposure early in life may induce 
long-lasting epigenetic changes in neurotransmission-related genes. For example, animal 
studies demonstrated that prenatal GC exposure leads to differential methylation of dopamine 
receptor D2 [50]. In humans, depressed mood during pregnancy leads to decreased levels of 
methylation in the promoter of the SLC6A4 gene, encoding the serotonin transporter, in 
maternal peripheral leukocytes and in umbilical cord leukocytes collected from their infants at 
birth [51]. Such changes may affect how the individual senses/processes/responds to 
environmental stimuli and may explain, in part, the increased vulnerability for 
neuropsychiatric disorders later in life.  
In addition to particular gene epigenetic changes, stress/GC have a strong impact in the 
epigenome (elegantly reviewed in [52]. Human studies on different cohorts have shown that 
early life maltreatment induces long-lasting methylation changes in the genome [53-55] while 
recent animal-based evidence suggest that the epigenomic landscape is also strongly 
correlated with gestational maternal adversity [56] and even with natural variations in 
maternal care [57]. In addition to methylation, gene expression can be further controlled by 
hydroxymethylation and diverse histone modifications, adding additional layers of 
complexity to the GC-driven changes that may predispose individuals to the development of 
brain pathologies. 
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SUSTAINED GR ACTIVATION AND  
NEURODEGENERATION IN AD 
 
Alzheimer‘s disease (AD) is an age-related neurodegenerative disorder characterized by 
slow and progressive dementia while the major histopathological hallmarks are senile plaques 
containing amyloid beta (Aβ) deposits and intracellular neurofibrillary tangles (NFT) made of 
hyperphosphorylated forms of the cytoskeletal protein Tau [58-60]. Aβ is the proteolytic 
product of the bigger transmembrane protein called amyloid precursor protein (APP), which 
is sequentially cleaved by β-secretase (BACE-1) and γ-secretase (enzymatic complex of 
proteins) resulting in the production of Aβ; this cellular pathway is often called APP 
misprocessing. Many studies have demonstrated that APP misprocessing and Aβ trigger AD 
neuropathological processes such as synaptic malfunction (impairing mechanisms of synaptic 
plasticity, e.g., LTP), neuronal atrophy and synaptic loss as well as mitochondrial 
dysfunction, oxidative stress and glial activation.  
While still debated, it is suggested that Aβ also triggers abnormal Tau 
hyperphosphorylation leading to the formation of NFTs and neuronal loss in AD brain. 
Indeed, accumulating data suggest the involvement of Tau protein in the detrimental effects 
of Aβ as use of Tau-KO blocked the Aβ neurotoxic effects [61-64]. Further support of the 
essential role of Tau in the establishment of AD pathology is based on the clinical findings 
that have consistently shown that the cognitive deficits in AD patients correlate with NFTs 
rather with Aβ deposition. Indeed, hyperphosphorylated and aggregated Tau resulting in 
NFTs is associated with neuronal loss. Gomez-Isla et al. [65] demonstrated that strong 
correlation of neuronal loss in cerebral cortex and increased NFT burden with disease 
progression; no such correlation was found with Aβ. Furthermore, reduction of hippocampal 
volume in AD patients was associated with phosphorylated Tau, but not Aβ levels in cerebral 
spinal fluid (CSF) [66].  
Several risk factors have been suggested for AD while recent evidence supports an 
etiopathogenic role of chronic stress and glucocorticoid hormones in the establishment and 
development of AD pathology [67, 68]. Clinical studies report high cortisol levels, measured 
in plasma, saliva or CSF, of AD patients indicative of altered HPA axis [69-73] while the 
increase of cortisol levels is negatively associated with memory scores in AD patients [74, 
75]. Furthermore, Hartman et al. [76] monitored the 24hr secretory pattern of plasma cortisol 
in AD patients finding a higher mass of cortisol release; however, the diurnal changes in 
cortisol levels were not altered. Since chronic elevation of GC levels is known to impair 
memory and cognitive performance, it is speculated that GCs play a role in progressive 
cognitive decline in AD. Indeed, it is unclear whether high GCs are a cause or a consequence 
of the disease as one of the explanations of high GC levels in AD patients is the deregulation 
of feedback inhibition of the HPA axis, particularly in relation to psychogenic stressors, 
occurring at the level of the hippocampus, a region significantly damaged in AD brains.  
It is noteworthy that many clinical and experimental reports suggest a reduction of adult 
neurogenesis in AD hippocampus while the same is true for chronic stress conditions [77-79]. 
Reduction of hippocampal adult neurogenesis was shown to increase HPA activity implying 
that this region is involved in hippocampal feedback regulation of HPA axis during stress 
[80]. Thus, high GCs can aggravate hippocampal memory processes in AD by having a 
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negative effect on hippocampal neurogenesis, which may, in turn, contribute to maintenance 
of deregulated HPA axis.  
 
 
GC IMPACT ON AD NEURODEGENERATIVE MECHANISMS 
 
Clinical studies show that chronic stress is a risk factor in AD pathogenesis and it also 
lowers the age of onset of the familial form of AD [67, 68]. Indeed, it has been evoked that 
chronic stress is among the principal factors that contributes to development of AD [77]. A 
principal target of GCs is hippocampus, which is a main target area for AD pathology and 
chronic stress (Figure 1). The hippocampal dysfunction in AD has significant detrimental 
consequences on declarative, spatial and contextual memory processes. As hippocampal 
neurons have very strong GR expression and are intimately involved in regulation of HPA 
axis, there has been a great deal of interest in how high cortisol levels and stress impact the 
deterioration of hippocampal functions caused by toxic Aβ and Tau hyperphosphorylation in 
AD.  
Previous studies show that elevated GC levels and exposure to chronic stress increase Aβ 
production in AD transgenic mouse models exacerbating their memory deficits [81, 82], 
Specifically, chronic immobilization stress in amyloid precursor protein (APP)V717ICT-100 
transgenic mice (this APP mutation is known for aggressive early onset AD) evoked 
acceleration and greater severity of memory deficits and increased extracellular Aβ deposits. 
Similarly, Green at al [81] showed that prolonged treatment with the synthetic GC, 
dexamethasone, triggers APP misprocessing resulting in increased Aβ levels using both in 
vitro and in vivo approaches (neuronal N2A cell line and pre-pathological 3xTg-AD young 
mice). In addition, the same study also demonstrated transcriptional up-regulation of APP and 
β-secretase expression by GR (both contain GRE in their promoter region).  
Similarly, other in vitro studies have confirmed that GCs trigger APP misprocessing 
without influencing the non-amyloidogenic pathway, i.e., the other cellular cascade of APP 
cleavage/processing [83]. Similar observations were made in middle-aged rats in which the 
amyloidogenic potential of chronic stress (chronic unpredictable stress paradigm) and 
prolonged GC treatment was demonstrated insofar that both treatments were found to drive 
APP processing towards the generation of Aβ and its precursor molecule (C99), both of 
which have neurotoxic and cognition-impairing properties [84]. This study also showed that 
GC/stress increased β-secretase (BACE-1) levels as well members of γ-secretase complex 
(Nicastrin). Given that stressful stimuli occur intermittently over the lifetime, and that their 
effects may be cumulative, an important finding by Catania et al., [84] was that GC potentiate 
the APP misprocessing pathway in previously stressed animals of AD model (Aβ-infused 
rats).  
Interestingly, clinical studies suggested that the stress-related neuropsychiatric disorder, 
depression, is a risk factor for the development of AD pathology as the history of depression 
is correlated with increases of amyloid plaques and NFT [85]. In addition, other studies 
suggested the utility of measurements of the various APP cleavage products as biomarkers to 
discriminate between subjects undergoing normal aging from those suffering from depression 
or AD [86-89]. Interestingly, more recently, some studies report the influence of anti-
depressant drugs on the proteolytic cleavage of APP suggesting its anti-amyloidogenic role 
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[89, 90] while many antidepressants are shown to normalize the HPA axis and the resulting 
GC levels which are increased in many depressed patients and models of stress-driven 
depression. 
Besides APP misprocessing, high levels of GC trigger the other main AD 
neurodegenerative pathway, the aberrant hyperphosphorylation of Tau protein. Among the 
first reports suggesting a potential connection between GC and Tau was the study by Stein-
Behrens et al. which demostrated high GC levels exacerbated neuronal loss induced by kainic 
acid injection in hippocampus while in parallel increased Tau immunoreactivity. Later on, it 
was shown that treatment with synthetic dexamethasone for 7 days in 3xTg AD mouse model 
resulted in Tau accumulation in somatodendritic compartment of neurons in hippocampus, 
amygdala and cortex [81].  
 
 
Figure 1. Glucocorticoids (GCs) and Stress impact on AD neurodegenerative mechanisms. The 
schematic presentation reflects the triggering role of high GC levels and chronic stress on AD cellular 
mechanisms based on experimental evidence using animal and cellular AD models. Prolong exposure 
to GC and/or stress activates amyloidogenic cellular pathway resulting in the sequential cleavage of 
APP by β- and γ-secretase which produces Aβ. Next, the cytoskeletal protein Tau, mainly found at 
neuronal axon (rdown (dark) part in the healthy neuron scheme), is aberrantly hypersphosphorylated 
through the activation of different kinases (e.g., GSK3-β and cdk5) which results in Tau 
somatodendritic accumulation (upper (dark) part in in diseased neuron scheme). In addition, abnormal 
conformation and caspase 3-mediated truncation of Tau occurs together with a parallel dysregulation of 
the molecular chaperones (e.g., Hsp90 and Hsp70) facilitating reduced Tau degradation and increased 
Tau oligomerization and ultimately, aggregation (see panel on the right). The above cellular cascades 
result in neuronal atrophy and loss leading to the establishment of cognitive impairment. 
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In addition, Sotiropoulos et al., [91] showed that chronic stress or GC treatment triggers 
Tau hyperphosphorylation in different epitopes implicated in cytoskeletal pathology and 
synaptic loss in AD patients (e.g., pSer262) [92, 93]; note that these epitopes are correlated 
with hippocampal atrophy in AD patients (e.g., pThr231) [94]. Indeed, clinical studies report 
a strong correlation between the extent of Tau hyperphosphorylation (e.g., Thr231 and Ser262 
residues) and severity of impairments of memory, speed of mental processing, and executive 
functions [95-97].. Futhermore Tau hyperphosphorylation is associated with synaptic loss and 
memory impairment in experimental animals [98] that could be also related with the stress-
induced synaptic and memory loss.  
Albeit specific Tau phosphoepitopes maybe differentially regulated by chronic stress and 
prolonged GC treatment, the overall in vitro and in vivo evidence [83] clearly implicates GCs 
as a key mediator of the cellular response to stress. Nevertheless, other studies have also 
suggested the contribution of other stress-related molecules, e.g., corticotrophin-releasing 
hormone [99, 100]. Furthermore, in vitro studies suggest the mediation of glycogen synthase 
kinase 3 (GSK3) or CDK5 in the above GC- and stress-triggered Tau hyperphosphorylation, 
both known to lead to microtubule disruption as well as formation of NFTs [83]. In parallel, 
GC were also shown to increased Tau accumulation by affecting turnover of the protein [83], 
which may involve reduced degradation through dysregulation of molecular chaperones 
responsible for Tau proteostasis (e.g., Hsp90, Hsp70 [101]). Interestingly, Hsp90 and Hsp70 
serve to maintain the glucocorticoid receptor (GR) in a high affinity state (as previously 
discussed) and thus, offering a clear cross-point between GC/GR cellular signaling and Tau 
degradation machinery. This reduced degradation could facilitate the increased aggregation of 
Tau into insoluble forms triggered by stress in P301L-Tau Tg mice [mice expressing human 
Tau carrying the most common Tau mutation (P301L-Tau)]. In addition, chronic stress also 
promotes C-terminal truncation of Tau by caspase-3 and, abnormal conformation of Tau in 
the hippocampus of the same animals. Indeed, both truncation and abnormal conformation of 
Tau precede its aggregation and formation of neurofibrillary tangles [99, 102, 103] thus 
serving as early markers of disease. The Tau-C3 species have been suggested to contribute to 
misfolding of Tau into a conformation that can nucleate and recruit other Tau molecules into 
aggregates [99, 103, 104], which are shown to be neurotoxic and related to neuronal loss 
[105].  
 
 
GLUCOCORTICOID ROLE IN THE ONSET AND PROGRESSION OF 
PARKINSON’S DISEASE 
 
Parkinson‘s disease (PD), the most common neurodegenerative movement disorder, is 
characterized by preferential loss of dopaminergic neurons in the substantia nigra pars 
compacta (SNpc) and dopamine depletion in striatum that underlies the appearance of motor 
symptoms such as akinesia, resting tremor, rigidity and postural instability. The main 
histopathological characteristic in PD brain is Lewy bodies (LBs), which are proteinaceous 
inclusions containing the presynaptic protein, alpha-synuclein, and are found in many 
different brain regions far beyond SN and striatum; e.g., cerebral cortex, limbic system, 
hypothalamus as well as the autonomic nervous system that are also affected in PD brain 
[106-108]. Thus, in addition to motor symptoms due to SN and striatum neurodegeneration 
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and lessions, PD patients with cortical LBs also suffer from dementia and visual 
hallucinations [109].  
While several gene mutations have been identified in the familial forms of PD, the 
majority of PD cases are sporadic with unknown etiology. Different cellular mechanisms 
have been suggested to be involved in PD neurodegeneration and dopaminergic neuronal loss 
such as oxidative and nitrative stress, mitochondrial dysfunction and deregulated intracellular 
calcium levels, damaged proteostasis related to alpha-synuclein aggregation [110]. Like in 
AD, deregulated HPA activity is also reported in PD patients. Specifically, previous studies 
[76, 111-113] including our work [114] show that plasma cortisol levels are significantly 
higher in idiopathic PD patients compared to control subjects; however the cortisol levels are 
not related to disease duration or to L-3,4-dihydroxyphenylalanine (L-DOPA) treatment. 
Interestingly, the diurnal mode of cortisol secretion in PD patients, in particular the normally 
quiescent nocturnal cortisol secretory pattern, is affected [76].  
Furthermore, monoaminergic neurotransmission in hypothalamus, the first compartment 
of HPA axis, is also affected in PD patients who exhibit reduced levels of dopamine, 
serotonin and noradrenaline in this brain area [115, 116] followed by reduced density of 
dopamine receptors [117]. Notably, this reduction was not altered by dopamine medication, 
which is often used in PD patients. Future studies are necessary to clarify whether the 
deregulation of HPA axis in PD patients is situated at the hypothalamic and/or the adrenal 
level as Lewy body pathology is observed in both regions.  
 
 
THE NEURODEGENERATIVE POTENTIAL OF  
GC IN PD PATHOLOGY 
 
The deregulated HPA axis and the subsequent elevated GC levels in PD patients reflects 
the role of stress which was suggested as one of the earliest proposed causes of PD. Although 
it may not be a major etiological factor, there are clinical reports showing that chronic stress 
triggers the appearance of PD symptoms or exacerbates the motor symptoms [118, 119]. 
Furthermore, experimental studies demonstrate that stressors such as food deprivation or 
tailshock aggravate motor deficits in the 6-hydroxydopamine (6-OHDA) PD model (6-
hydroxydopamine local injections lesions the nigrostriatal pathway) [120]. Using the same 
model, Smith et al. [118] showed that chronic stress exposure (restraint) before the 6-OHDA 
injection worsened the 6-OHDA-driven motor deficits, aggravated the neurodegeneration of 
nigrostriatal system and completely blocked compensatory recovery of motor tasks.  
How does high stress level of GC-GR exacerbate motor impairments following 
nigrostriatal lesions? GCs are known to profoundly shape the dopaminergic neurotransmitter 
system, exerting differential or heterogeneous effects depending on whether the dopaminergic 
projections arise from the ventral tegmentum area (VTA) or the SNpc. While plethora of 
studies have monitored the impact of GC on the limbic arm of dopamine neuronal circuitry 
related to behavioral changes as well as neuropsychiatric diseases, our knowledge about the 
exact GC influence on motor-related dopamine neuronal networks is very limited. There is 
lack of evidence about the impact of chronic GC elevation on nigral and striatal neurons or 
glia and how this contributes to nigrostriatal degeneration and motor impairments. Analysis 
of GR in PD brain revealed that global GR levels were lower in SNpc and higher in putamen 
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compared to control subjects and these results were recapitulated in MPTP (1-methyl 4-
phenyl 1,2,3,6-tetrahydropyridine)-treated mice [114].  
However, the cell types in which GR changes occur have not been identified. 
Interestingly, high GR levels in putamen of PD patients raises the possibility that 
dopaminergic nerve terminal degeneration induces upregulation of GR in striatal neurons 
and/or glia. In a study by Barrot et al. [121], GCs in SNpc or in dorsolateral striatum were 
found not to modify either tyrosine hydroxylase levels or dopamine transporter activity. On 
the contrary, adrenalectomy and the subsequent loss of corticosterone resulted in reduced D1 
dopamine receptor in dorsolateral striatum suggesting that neurons expressing dopamine 
receptors may represent a target of GC-GR actions for basal ganglion regulation of 
movement. While the molecular mechanisms by which high GC through GR activity 
exacerbate motor deficits are not well understood, it is possible that they alter glutamatergic 
synapses in striatum that are under dopamine regulation. 
 
 
ROLE OF GLUCOCORTICOID RECEPTOR IN REGULATION OF 
INFLAMMATION IN PARKINSON’S DISEASE 
 
Chronic inflammation mediated principally by activated microglia, astrocytes and 
infiltrating T cells is a major neuropathological characteristic of PD. Evidence from recent 
genome-wide studies point to involvement of the immune system in the etiology of idiopathic 
PD. A number of susceptibility loci identified relate to genes expressed in immune cells such 
as HLA-DQB1, LRRK2 or BST-1 [122, 123]. In addition, identified PD risk factors [such as 
age, environmental toxins (e.g., heavy metals or pesticides,) traumatic brain injury, bacterial 
or viral infections] activate immune responses in periphery and brain.  
Using radiolabelled ligand 
11
C-PK-11195 for translocator protein, Positron Emission 
Tomography (PET) studies in PD patients revealed an early activation of microglia in many 
brain regions including basal ganglia and substantia nigra [124, 125]. Furthermore, post-
mortem studies as well as analyses of serum and cerebrospinal fluid from PD showed high 
levels of pro-inflammatory mediators such as TNF-, IL-1, iNOS, IFN- and COX-2 [126]. 
In line with observations in PD patients, presence of inflammatory mediators and glial 
reactivity in striatum and substantia nigra is a key feature in many of the experimental animal 
models of PD. For example, treatment of mice or monkeys with neurotoxin 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) which selectively induces degeneration of 
nigrostriatal pathway, 6-hydroxydopamine lesion of nigro-striatal pathway in rodents or 
toxicity induced by alpha-synuclein injection [126, 127].  
Among all the brain regions, substantia nigra has one of highest density of microglia. 
Activated microglia functioning as innate-immune competent cells are likely involved in 
releasing the above inflammatory molecules, thereby inducing dopamine neurodegeneration. 
Indeed the important role of these pro-inflammatory mediators in promoting degeneration of 
dopaminergic neurons of substantia nigra was demonstrated using mice with specific 
knockout of these genes [128-131]. Many of the pro-inflammatory mediators found in PD 
patients are transcriptional targets of GR. The synthetic analogue of GCs, dexamethasone, 
was shown to attenuate dopamine neuronal loss by precluding activated microglia from 
releasing toxic inflammatory molecules [132, 133]. In adrenalectomized mice (lacking 
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endogenous production of GCs), dopamine neuronal loss was augmented following MPTP 
intoxication indicating that endogenous GCs do play a role in protecting dopamine neurons 
[134] Examination of GR in microglia revealed an increase in nuclear localization of GR 
following MPTP treatment in mice, which coincided with rise in systemic corticosterone 
levels indicating that GR is activated in microglia during degeneration of dopamine neurons 
[114]. The unequivocal evidence that GR in microglia normally protects dopamine neurons 
appeared in a study using mice in which GR gene is deleted in microglia/macrophages. MPTP 
treatment in these mice resulted in increased dopamine neuronal loss as well as increased 
microglial activation and expression of pro-inflammatory mediators [114]. Indeed, the 
absence of GR in microglia resulted in sustained activation of NF-B as was shown in these 
microglial GR mutants. The above finding has a significant relevance for PD pathogenesis as 
nuclear expression of p65 subunit of NF-B, indicative of transcriptional activity, was found 
in substantia nigra microglia of PD post-mortem [135].  
Chronic inflammation and sustained activation of glia in PD suggests that processes 
involved in regulation of glial activation and expression/secretion of inflammatory mediators 
are likely compromised. Chronic inflammation, an important component of pathology in 
neurodegenerative diseases, is suggested to be a maladaptive response of homeostasis as 
successful inflammatory response has a resolution phase which is an active process that 
enables restoration of homeostatic set points [136, 137]. Inflammation mediated by immune-
competent cells including microglia is normally a very tightly regulated process. The 
immune-regulatory processes are affected in aging leading to increased susceptibility to 
infections and immune activation. Thus in aging, microglia show enhanced sensitivity to 
inflammatory stimuli - a process called ―priming‖ which could be also induced by chronic 
stress and deregulated HPA axis. In this regard, there are several studies showing that 
chronically elevated GC levels in response to different stressors cause pro-inflammatory 
cytokine production and sensitization or ―priming‖ of microglia. Importantly, subsequent 
inflammatory or toxic stimulus results in aggravatation of neuronal injury [138-140]. Aging is 
associated with chronically high GC levels and immuno-senescence exemplified by a 
sustained low production of pro-inflammatory molecules [141]. Thus, in contrast to their 
well-known anti-inflammatory actions, in fact high and sustained GCs can exacerbate 
inflammation. However, it is currently not known whether GR transcriptional activity 
regulating inflammatory response of microglia is compromised in AD and PD pathological 
conditions where deregulated HPA axis and sustained high GC levels of are found.  
 
 
GC-DRIVEN BRAIN PROGRAMMING AND  
NEURODEGENERATIVE PATHOLOGIES 
 
Although Alzheimer‘s disease (AD) is often seen as an age-related neurodegenerative 
disorder, recent evidence suggests that early life events may play a role in the onset of the 
disorder (Borenstein, A.R.; Early-life risk factors for Alzheimer disease. Alzheimer Dis. 
Assoc. Disord., 2006). In this perspective, AD is probably not determined by a single 
etiologic factor, but results from the interplay between genetic and environmental factors 
throughout life, being a possible explanation why monozygous twins can be discordant for 
AD.  
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Albeit there is still controversy and the literature is sparse, it has been suggested that 
early life adverse events such as maternal stress, intrauterine infections, poor maternal and 
perinatal nutrition can potentially predispose to AD eventually by epigenetic programing of 
specific genes/pathways related to AD neurodegeneration. For example, early-life lead 
exposure of older rats and primates induces overexpression of the amyloid precursor protein 
and its amyloid beta (Aβ) product, both characteristically found in AD brain as will be 
discussed later in this chapter. One interesting finding was that cognitive impairment was 
only observed in mice exposed to lead [142], highlighting the relevance of the ―window of 
opportunity‖ for some environmental factors to trigger the disease.  
Similarly, Tau hyperphosphorylation and accumulation, the other main histopathological 
characteristic of AD pathology) was elevated in both aging rodents and primates previously 
exposed to lead at younger age, [143] suggesting the potential impact of early-life stress 
exposure to the precipitation of AD neurodegeneration later in life. Interestingly, a recent 
study has also highlighted the GC-related epigenetic drive in the establishment of AD 
pathology in the brain of CK-p25 AD mouse model (exhibiting Tau pathology). These Tg 
mice exhibit increased levels of HDAC2 associated with cognitive impairment, which seems 
to be mediated through glucocorticoid receptor induced HDAC2 transcription [144].  
Furthermore, the role of early life stressful events in the etiopathogenesis of another 
neurodegenerative disorder, Parkinson‘s disease (PD) has emerged in the last years. In an 
interesting study, pups of female animals exposed to lipopolysaccharide (LPS), a bacterial 
endotoxin, during pregnancy, showed loss of dopaminergic neurons. This suggests that high 
LPS levels in mothers might interfere with the dopaminergic neurons in the fetus enhancing 
the susceptibility to PD [145].  
Accordingly, different stressful stimuli could act cumulatively with the developmental 
stress exposure representing the first imprint in the developing brain, determining the PD 
phenotype characterized at the pathological level by a deficient substantia nigra with a low 
burden of DA neurons at birth corresponding to a limited nigro-striatal neurochemical reserve 
[146]. The low number of DA neurons in the substantia nigra reflecting the developmental 
damage may remain subclinical during life. Thus, later exposure to the same or other DA 
neuron-targeted toxicants might attack the few residual neurons leading to insurgence of PD. 
 
 
CONCLUSION  
 
Accumulating evidence suggests the neurodegenerative potential of chronic stress and 
elevated GC levels in triggering clinical symptoms and participating in neuropathological 
mechanisms and processes in AD and PD, two devastating age-related neurodegenerative 
disorders. High circulating GC (cortisol) levels and deregulated HPA axis observed in 
patients of both disorders imply that GR activity in the affected regions is most likely 
compromised but the cause-consequence interrelationship between elevated GC levels and 
development of neurodegenerative pathology remains unclear. While the ramifications of 
prolonged exposure to GC stress are many, being causally implicated in immunosuppression, 
metabolic syndrome, diabetes and others, our current understanding of the exact actions of 
GC on these neurodegenerative diseases, although limited, opens a window of opportunities 
to identify the various parameters that contributes to stress/GC-driven brain pathology. As 
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both context and cell type determine GR functions, future works using, e.g., cell-specific 
mouse models of GR activation/inactivation should shed light on their roles in pathological 
brain aging and onset of neurodegenerative disorders such as AD and PD. 
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